|
|
Article: Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors.
- Article from:
- PR Newswire
- Article date:
- June 2, 2007
CopyrightCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Studies Investigating Vidaza in Alternate Dosing Schedules in MDS and in Combination with Valproic Acid for Solid Tumors Presented at the American Society of Clinical Oncology 43rd Annual Meeting
- In alternate dose trial, transfusion independence achieved for 65% to 80% of patients transfusion dependent at baseline
CHICAGO, June 2 /PRNewswire-FirstCall/ -- Pharmion Corporation reported today the interim results of several Vidaza(R) (azacitidine for injection) studies in the treatment of hematologic malignancies and advanced solid tumors. These data were presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, ...